• 1. An insight into the hybridization mechanism of hairpin DNA physically immobilized on chemically modified graphenes
  Adeline Huiling Loo,Alessandra Bonanni,Martin Pumera Analyst, 2013,138, 467-471
• 2. An autonomous self-optimizing flow machine for the synthesis of pyridine–oxazoline (PyOX) ligands?
  Eric Wimmer,Daniel Cortés-Borda,Solène Brochard,Elvina Barré,Charlotte Truchet,Fran?ois-Xavier Felpin React. Chem. Eng., 2019,4, 1608-1615
• 3. An integrated cathode and solid electrolyte via in situ polymerization with significantly reduced interface resistance?
  Jialiang Yuan,Ran Dong,Yuan Li,Yang Liu,Zhuo Zheng,Yuxia Liu,Yan Sun,Benhe Zhong,Zhenguo Wu,Xiaodong Guo Chem. Commun., 2021,57, 13004-13007
• 4. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210
• 5. An integrated process of CO2 capture and in situ hydrogenation to formate using a tunable ethoxyl-functionalized amidine and Rh/bisphosphine system?
  Yu-Nong Li,Liang-Nian He,Xian-Dong Lang,Xiao-Fang Liu,Shuai Zhang RSC Adv., 2014,4, 49995-50002

5H-Indazol-5-one, 1,4,6,7-tetrahydro-1-methyl- (CAS No. 115215-92-4): A Comprehensive Overview

5H-Indazol-5-one, 1,4,6,7-tetrahydro-1-methyl- (CAS No. 115215-92-4) is a significant compound in the field of medicinal chemistry and pharmaceutical research. This compound belongs to the class of indazoles and has garnered considerable attention due to its potential therapeutic applications and unique structural properties. In this article, we will delve into the chemical structure, synthesis methods, biological activities, and recent research advancements related to this compound.

The chemical structure of 5H-Indazol-5-one, 1,4,6,7-tetrahydro-1-methyl- is characterized by a fused ring system consisting of a benzene ring and a pyrazole ring. The presence of the methyl group at the 1-position and the ketone group at the 5-position contributes to its distinct reactivity and biological properties. The compound's molecular formula is C₉H₁₂N₂O, with a molecular weight of approximately 168.20 g/mol.

Synthesis of 5H-Indazol-5-one, 1,4,6,7-tetrahydro-1-methyl- can be achieved through various methods. One common approach involves the condensation of an appropriate hydrazine derivative with a ketone or aldehyde followed by cyclization and oxidation steps. For instance, the reaction of 2-methylbutanamide with hydrazine hydrate in the presence of an acid catalyst can yield the desired product after subsequent steps such as reduction and oxidation. Recent advancements in green chemistry have also led to more environmentally friendly synthetic routes using catalysts like metal nanoparticles and microwave-assisted reactions.

The biological activities of 5H-Indazol-5-one, 1,4,6,7-tetrahydro-1-methyl- have been extensively studied in various contexts. One notable application is its potential as an anti-inflammatory agent. Research has shown that this compound can inhibit the production of pro-inflammatory cytokines such as TNF-α and IL-6 in vitro and in vivo models. Additionally, it has demonstrated promising results in reducing inflammation in animal models of arthritis and other inflammatory diseases.

Beyond its anti-inflammatory properties, 5H-Indazol-5-one, 1,4,6,7-tetrahydro-1-methyl- has also been investigated for its neuroprotective effects. Studies have indicated that it can protect neuronal cells from oxidative stress-induced damage by scavenging free radicals and modulating intracellular signaling pathways. This makes it a potential candidate for the treatment of neurodegenerative disorders such as Alzheimer's disease and Parkinson's disease.

In the realm of cancer research, 5H-Indazol-5-one, 1,4,6,7-tetrahydro-1-methyl- has shown antiproliferative activity against various cancer cell lines. Mechanistic studies suggest that it can induce apoptosis by disrupting mitochondrial function and activating caspase cascades. These findings have sparked interest in exploring its potential as a novel anticancer agent.

The pharmacokinetic properties of 5H-Indazol-5-one, 1,4,6,7-tetrahydro-1-methyl- are also crucial for its therapeutic development. Preclinical studies have demonstrated that it exhibits good oral bioavailability and favorable pharmacokinetic profiles in animal models. However, further research is needed to optimize its pharmacological properties for clinical applications.

Clinical trials are currently underway to evaluate the safety and efficacy of 5H-Indazol-5-one, 1,4,6,7-tetrahydro-1-methyl- in human subjects. Early-phase trials have shown promising results in terms of tolerability and preliminary efficacy in treating inflammatory conditions and certain types of cancer. These trials are essential for advancing our understanding of the compound's therapeutic potential and guiding future drug development efforts.

In conclusion, 5H-Indazol-5-one, 1,4,6,7-tetrahydro-1-methyl- (CAS No. 115215-92-4) is a multifaceted compound with diverse biological activities that hold significant promise for various therapeutic applications. Ongoing research continues to uncover new insights into its mechanisms of action and potential clinical uses. As our understanding deepens, this compound may play a pivotal role in developing novel treatments for inflammatory diseases, neurodegenerative disorders, and cancer.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)